Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines

Matalliotakis, Ioannis; Goumenou, Anastasia G.; Koumantakis, Georgios; Neonaki, M; Koumantakis, E.; Dionyssopoulou, Eva; Athanassakis, Irene; Vassiliadis, S.

doi:10.1016/s1567-5769(02)00216-3

Cited by 87 publications

(55 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analyzing the VEGF serum levels in this present study, we demonstrated that the VEGF serum levels were statistically significantly higher in endometriosis patients compared to the control (P50.0001) which is in agreement with the findings reported by Matalliotakis et al [2003] in the Caucasian population (P50.001) but in contrast with those conducted by Kianpour et al [2013]. Additionally, we reported a significant association of the +936 CT genotype with an increased VEGF serum levels than the CC and TT genotypes (P50.0001).…”

Section: Discussionsupporting

confidence: 93%

Vascular endothelial growth factor (−460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population

Henidi

Kaabachi

Naouali

et al. 2015

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Vascular endothelial growth factor (−460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population

Henidi

Kaabachi

Naouali

et al. 2015

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

show abstract

“…Some studies have actually reported no significant difference in VEGF serum levels in patients with endometriosis compared with controls [24,25]. In contrast, other authors have shown a significant increase in circulating levels of VEGF among women with endometriosis [20,21,22,23]. In our study, we found no significant modulation of VEGFA mRNA levels in the peripheral blood of patients with endometriosis compared to controls.…”

Section: Discussioncontrasting

confidence: 89%

“…Previous studies have indicated a significant increase in VEGF and its mRNA expression in endometriotic lesions compared to controls or eutopic endometrium [15,16,17,18,19]. Contradictory results have been reported concerning peripheral blood levels of VEGF in women with or without endometriosis; some published data reported higher levels in cases of endometriosis [20,21,22,23], while other data reported no differences at all [24,25]. …”

Section: Introductionmentioning

confidence: 99%

Matrix Metalloproteinase-3 mRNA: A Promising Peripheral Blood Marker for Diagnosis of Endometriosis

Sanctis

Elmakky

Farina³

et al. 2010

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: Endometriosis is an invasive disease. Its diagnosis depends on laparoscopy, which is traumatic and associated with potential complications. The aim of this study was to develop a rapid, reliable, and less invasive diagnostic test for endometriosis. We hypothesized that genes related to cell invasion would be transcriptionally upregulated in endometriosis, and tested whether blood levels of their transcripts might be used as biomarkers of endometriosis.Methods:We used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) to quantify the mRNA levels of vascular endothelial growth factor A (VEGFA), matrix metalloproteinase-3 (MMP-3), and MMP-9 in peripheral blood from 20 patients with mild/intermediate endometriosis, 20 patients with severe endometriosis and 20 endometriosis-free subjects. Results:Our results indicate that circulating mRNA for MMP-3 is significantly higher in patients with endometriosis than in control patients, regardless of the degree of severity. Conversely, the level of circulating mRNA for VEGFA and MMP-9 did not distinguish patients from controls. Conclusion: MMP-3 mRNA is a promising peripheral blood marker that discriminates between patients with endometriosis and healthy subjects. Our results support the possibility of finding genes suitable for diagnostic qRT-PCR for endometriosis in peripheral blood and should be explored further.

show abstract

“…There is evidence that these drugs possess anti-angiogenic activity as well. While estrogen increases VEGF-A expression, 33 progesterone, dydrogesterone and dihydrodydrogesterone, 60 such as danazol, 61 reduce VEGF-A levels. Importantly, dienogest, an oral progestin, inhibited development and maturation of neovessels in a rat endometriosis model.…”

mentioning

confidence: 99%

Angiogenesis as a Therapeutic Target in Endometriosis

Djokovic

Calhaz‐Jorge

2014

Acta Med Port

View full text Add to dashboard Cite

RESUMOIntrodução: A angiogénese é um factor determinante no estabelecimento e desenvolvimento das lesões de endometriose. Material e Métodos:Foram revistos os artigos indexados na PubMed e incluídos os estudos mais relevantes, publicados até Janeiro de 2014, sobre a angiogénese nas lesões de endometriose e/ou estratégias anti-angiogénicas para o tratamento desta doença ginecológica.Resultados: O presente artigo fornece um resumo conciso dos mecanismos moleculares conhecidos que promovem a vascularização das lesões de endometriose, podendo servir como alvos terapêuticos potenciais. Apresenta-se também uma revisão sistemática dos agentes anti-angiogénicos, inclusivos e exclusivos, que já foram avaliados em culturas de células, modelos animais e/ou doentes com endometriose. Discussão e Conclusão: A integração das estratégias anti-angiogénicas na terapêutica multimodal de endometriose será condicionada pelos resultados de avaliações futuras da verdadeira eficácia desses tratamentos, do risco de desenvolvimento de resistência aos medicamentos e da incidência de efeitos colaterais inaceitáveis. Palavras-chave: Inibidores da Angiogénese/uso terapêutico; Endometriose/terapêutica. ABSTRACT Introduction:Angiogenesis is a key factor for the successful establishment and growth of endometriotic lesions. Material and Methods:We performed a literature search in PubMed and reviewed the most pertinent studies published until January 2014 and focused on the endometriosis-associated angiogenesis and/or anti-angiogenic strategies for the treatment of this gynecological disorder. Results:The present review provides a concise summary of the known molecular mechanisms that promote vascularization of endometriotic lesions and may serve as potential therapeutic targets. We also present a systematic overview of the inclusive and exclusive anti-angiogenic agents that have been already studied in cell cultures, animal models and/or endometriosis patients. Discussion and Conclusion:The integration of anti-angiogenic approaches in the multimodal management strategies for endometriosis patients will be conditioned by the outcomes of future assessments regarding the effectiveness of such treatments, the risk of drug resistance development and the incidence of unacceptable side effects.

show abstract

Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines

Cited by 87 publications

References 27 publications

Vascular endothelial growth factor (−460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population

Vascular endothelial growth factor (−460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population

Matrix Metalloproteinase-3 mRNA: A Promising Peripheral Blood Marker for Diagnosis of Endometriosis

Angiogenesis as a Therapeutic Target in Endometriosis

Contact Info

Product

Resources

About